JP2024016207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016207A5 JP2024016207A5 JP2023191314A JP2023191314A JP2024016207A5 JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5 JP 2023191314 A JP2023191314 A JP 2023191314A JP 2023191314 A JP2023191314 A JP 2023191314A JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5
- Authority
- JP
- Japan
- Prior art keywords
- fab
- liquid suspension
- hvegf
- eye
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006194 liquid suspension Substances 0.000 claims 31
- 241000702421 Dependoparvovirus Species 0.000 claims 14
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims 10
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims 10
- 230000001105 regulatory effect Effects 0.000 claims 7
- 108091026890 Coding region Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 210000000234 capsid Anatomy 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 229960003876 ranibizumab Drugs 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 102000007469 Actins Human genes 0.000 claims 2
- 108010085238 Actins Proteins 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 2
- 108010056354 Ubiquitin C Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010025421 Macule Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 208000002352 blister Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632775P | 2018-02-20 | 2018-02-20 | |
| US62/632,775 | 2018-02-20 | ||
| US201862663532P | 2018-04-27 | 2018-04-27 | |
| US62/663,532 | 2018-04-27 | ||
| PCT/US2019/018640 WO2019164854A1 (en) | 2018-02-20 | 2019-02-19 | Compositions for treatment of wet age-related macular degeneration |
| JP2020543914A JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Division JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016207A JP2024016207A (ja) | 2024-02-06 |
| JP2024016207A5 true JP2024016207A5 (OSRAM) | 2024-08-13 |
Family
ID=67688300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2023191314A Pending JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12558434B2 (OSRAM) |
| EP (1) | EP3755804A4 (OSRAM) |
| JP (2) | JP2021516671A (OSRAM) |
| KR (1) | KR20210022524A (OSRAM) |
| AU (2) | AU2019223963A1 (OSRAM) |
| CA (1) | CA3090293A1 (OSRAM) |
| IL (1) | IL276777B2 (OSRAM) |
| MA (1) | MA51916A (OSRAM) |
| SG (1) | SG11202007252VA (OSRAM) |
| WO (1) | WO2019164854A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018130284A1 (en) * | 2017-01-12 | 2018-07-19 | Telefonaktiebolaget Lm Ericsson (Publ) | Anomaly detection of media event sequences |
| CA3076905A1 (en) * | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| US11360969B2 (en) * | 2019-03-20 | 2022-06-14 | Promethium, Inc. | Natural language based processing of data stored across heterogeneous data sources |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| CA3168387A1 (en) * | 2020-02-28 | 2021-09-02 | The Trustees Of The University Of Pennsylvania | Treating autosomal recessive bestrophinopathies and methods for evaluating same |
| CN115397465B (zh) * | 2020-04-24 | 2026-04-24 | 美国西门子医学诊断股份有限公司 | 用于针对抗体的免疫测定的校准和质量控制试剂 |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| WO2022079453A1 (en) | 2020-10-16 | 2022-04-21 | Gyroscope Therapeutics Limited | Nucleic acid encoding an anti-vegf entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration |
| IL303317A (en) * | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20240335562A1 (en) * | 2021-08-04 | 2024-10-10 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| KR102789747B1 (ko) * | 2021-12-29 | 2025-04-03 | 한국과학기술원 | Prox1 단백질에 중화 활성을 갖는 결합 분자 |
| EP4473011A1 (en) * | 2022-02-02 | 2024-12-11 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| EP4537856A1 (en) * | 2022-06-07 | 2025-04-16 | Chengdu Origen Biotechnology Co., Ltd. | Adeno-associated virus pharmaceutical composition and use thereof |
| WO2024238859A1 (en) * | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1978095A1 (en) | 1993-02-12 | 2008-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptor proteins for controlling signal transduction and ligands binding thereto |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| AU9036198A (en) | 1997-08-26 | 1999-03-16 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
| EP1003886A1 (en) | 1997-08-27 | 2000-05-31 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
| CA2318402A1 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| EP1053241A1 (en) | 1998-02-13 | 2000-11-22 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| CA2388432A1 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| GB2362884A (en) | 2000-05-30 | 2001-12-05 | Isis Innovation | Extended duration of airway gene therapy |
| CN1461342A (zh) | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| SG10202108118RA (en) | 2001-11-13 | 2021-08-30 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2975413T3 (es) | 2001-12-17 | 2024-07-05 | Univ Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas |
| WO2003068801A2 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
| US20040208847A1 (en) | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| HUE054805T2 (hu) | 2003-09-30 | 2021-09-28 | Univ Pennsylvania | Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik |
| EP3085389A1 (en) | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| WO2006132118A1 (ja) | 2005-06-09 | 2006-12-14 | Matsushita Electric Industrial Co., Ltd. | 振幅誤差補償装置及び直交度誤差補償装置 |
| CN105315323A (zh) | 2007-10-30 | 2016-02-10 | 健泰科生物技术公司 | 通过阳离子交换层析进行的抗体纯化 |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| KR101010352B1 (ko) | 2008-05-30 | 2011-01-25 | 삼성중공업 주식회사 | 전력 제어 장치 및 방법 |
| WO2010054007A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| BRPI1012321A8 (pt) | 2009-06-17 | 2016-09-27 | Abbott Biotherapeutics Corp | Anticorpos anti-vegf e seus usos |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN107828820B (zh) | 2010-10-27 | 2022-06-07 | 学校法人自治医科大学 | 用于向神经系统细胞导入基因的腺相关病毒粒子 |
| US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN107012171B (zh) | 2011-04-22 | 2021-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| EP3147295B2 (en) | 2011-08-24 | 2023-11-22 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| US20130090375A1 (en) | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| KR102467714B1 (ko) | 2012-11-08 | 2022-11-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
| ES2741502T3 (es) | 2013-02-08 | 2020-02-11 | Univ Pennsylvania | Cápside de AAV8 modificada para la transferencia génica para terapias de retina |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| JP6591956B2 (ja) | 2013-03-15 | 2019-10-16 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｍｐｓ１を治療するための組成物および方法 |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| NZ718926A (en) | 2013-10-11 | 2021-12-24 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
| AU2014359276B2 (en) | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| CA2946392A1 (en) | 2014-04-25 | 2015-10-29 | James M. Wilson | Ldlr variants and their use in compositions for reducing cholesterol levels |
| MY186389A (en) | 2014-05-13 | 2021-07-22 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CN108347932B (zh) | 2015-02-20 | 2022-09-13 | 衣阿华大学研究基金会 | 用于治疗遗传性眼病的方法和组合物 |
| EA201792500A1 (ru) | 2015-05-13 | 2018-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Aav-опосредованная экспрессия антител против гриппа и способы их использования |
| JP2018526003A (ja) | 2015-08-31 | 2018-09-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | イヌの癌を治療するためのキメラａａｖ−抗ｖｅｇｆ |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| EP3400014A1 (en) | 2016-01-08 | 2018-11-14 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| SG11201808440YA (en) | 2016-04-15 | 2018-10-30 | Regenxbio Inc | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| WO2017180936A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| MX2021011889A (es) | 2019-04-03 | 2021-10-26 | Regenxbio Inc | Tratamiento genico para patologias oculares. |
-
2019
- 2019-02-18 US US16/971,215 patent/US12558434B2/en active Active
- 2019-02-19 JP JP2020543914A patent/JP2021516671A/ja active Pending
- 2019-02-19 IL IL276777A patent/IL276777B2/en unknown
- 2019-02-19 CA CA3090293A patent/CA3090293A1/en active Pending
- 2019-02-19 MA MA051916A patent/MA51916A/fr unknown
- 2019-02-19 SG SG11202007252VA patent/SG11202007252VA/en unknown
- 2019-02-19 WO PCT/US2019/018640 patent/WO2019164854A1/en not_active Ceased
- 2019-02-19 KR KR1020207026455A patent/KR20210022524A/ko active Pending
- 2019-02-19 AU AU2019223963A patent/AU2019223963A1/en not_active Abandoned
- 2019-02-19 EP EP19757101.1A patent/EP3755804A4/en active Pending
-
2023
- 2023-11-09 JP JP2023191314A patent/JP2024016207A/ja active Pending
-
2025
- 2025-06-25 AU AU2025204780A patent/AU2025204780A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153418A5 (OSRAM) | ||
| JP2021516671A5 (OSRAM) | ||
| KR102616820B1 (ko) | 향상된 유전자 발현을 위한 조성물 및 방법 | |
| JP2025000642A5 (OSRAM) | ||
| JP2019518427A5 (OSRAM) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2020510424A5 (OSRAM) | ||
| JP2022552262A5 (OSRAM) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| JP2023545424A5 (OSRAM) | ||
| JP2022545967A5 (OSRAM) | ||
| JP2011512417A (ja) | 血管形成の阻害 | |
| JP2022522776A5 (OSRAM) | ||
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| US20130090375A1 (en) | Virus-mediated delivery of bevacizumab for therapeutic applications | |
| KR20240150793A (ko) | Vegf 결합 분자 및 이의 의약적 용도 | |
| JP2023545229A5 (OSRAM) | ||
| KR20240116840A (ko) | 변형된 aav 캡시드 단백질 및 이의 용도 | |
| CN117242183A (zh) | 用于治疗与血管生成相关的眼部疾病的组合物和方法 | |
| AU2024261900A1 (en) | Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus | |
| JP2023547832A5 (OSRAM) | ||
| US20240279324A1 (en) | Multispecific antagonists | |
| CN117736274A (zh) | 一种腺相关病毒衣壳蛋白及其用途 | |
| KR20240107201A (ko) | 항원-결합 분자 및 이의 용도 |